Yantai, China

Zongliang Liu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Luye Innomind Pharma Shijiazhuang Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zongliang Liu. Retrieved from https://idiyas.com/inventor/zongliang-liu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zongliang Liu: Innovator in VMAT2 Inhibition

Introduction

Zongliang Liu is a prominent inventor based in Yantai, China. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that inhibit VMAT2. His work is crucial for advancing treatments for diseases related to this target.

Latest Patents

Zongliang Liu holds 1 patent for his invention titled "VMAT2 inhibitor and preparation method therefor and application thereof." This patent describes a class of compounds that serve as VMAT2 inhibitors, focusing on a specific compound represented by formula (I), or its stereoisomers or pharmaceutically acceptable salts. The invention also details the preparation method and its application in creating medicaments for treating diseases associated with VMAT2.

Career Highlights

Zongliang Liu is affiliated with Luye Innomind Pharma Shijiazhuang Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in developing VMAT2 inhibitors positions him as a key player in the industry.

Collaborations

He collaborates with notable colleagues, including Bo Cui and Guangying Du, who contribute to his research and development efforts.

Conclusion

Zongliang Liu's work in VMAT2 inhibition represents a significant advancement in medical science, showcasing his dedication to improving therapeutic options for patients. His contributions are vital for the ongoing development of effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…